相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
Klaus Juergen Schmitz et al.
JOURNAL OF HEPATOLOGY (2008)
Is there room for improvement in adverse event reporting in the era of targeted therapies?
Maureen Edgerly et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma
Kelvin K. Ng et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
Causes of death in patients with unresectable hepatocellular carcinoma
O. F. M. Couto et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Melanie B. Thomas et al.
CANCER (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
Ronnie T. P. Poon et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells
Erica Novo et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Chronic viral hepatitis and hepatocellular carcinoma
Yagil Barazani et al.
WORLD JOURNAL OF SURGERY (2007)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Prevention and management of Gastroesophageal varices and variceal Hemorrhage in cirrhosis
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2007)
Angiogenic factor expression in hepatic cirrhosis
Alexandra Giatromanolaki et al.
MEDIATORS OF INFLAMMATION (2007)
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma
Joanna W. Y. Ho et al.
HEPATOLOGY (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma:: importance of angiopoietin-2 and hypoxia-induced factor-1α
H Wada et al.
LIVER INTERNATIONAL (2006)
Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma
AF Buckley et al.
HUMAN PATHOLOGY (2006)
A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
W Yeo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis
E Schiffer et al.
HEPATOLOGY (2005)
Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma
I-Shyan Sheen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?
Kuo-Shyang Jeng et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer
AB Sandler et al.
CLINICAL CANCER RESEARCH (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis
H Yoshiji et al.
GUT (2003)
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery
Y Chao et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Molecular pathogenesis of human hepatocellular carcinoma
SS Thorgeirsson et al.
NATURE GENETICS (2002)
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?
S Nair et al.
HEPATOLOGY (2002)
Estimating the world cancer burden: GLOBOCAN 2000
DM Parkin et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Clinical implications of circulating angiogenic factors in cancer patients
RTP Poon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Serum endostatin levels in patients with hepatocellular carcinoma
M Yamagata et al.
ANNALS OF ONCOLOGY (2000)
Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma
FQ An et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2000)
分享论文
